EA201492023A1 - Регуляторы пути комплемента и их применение - Google Patents

Регуляторы пути комплемента и их применение

Info

Publication number
EA201492023A1
EA201492023A1 EA201492023A EA201492023A EA201492023A1 EA 201492023 A1 EA201492023 A1 EA 201492023A1 EA 201492023 A EA201492023 A EA 201492023A EA 201492023 A EA201492023 A EA 201492023A EA 201492023 A1 EA201492023 A1 EA 201492023A1
Authority
EA
Eurasian Patent Office
Prior art keywords
regulators
application
complex way
complex
way
Prior art date
Application number
EA201492023A
Other languages
English (en)
Other versions
EA027113B1 (ru
Inventor
Кристофер Майкл Адамс
Чарльз Бабу
Цзянь Дин
Такеру Ехара
Кит Джендза
Нань Цзи
Раджешри Ганеш Карки
Тосио Каванами
Лян Сюэ
Нелло Майнольфи
Джеймс Дж. Пауэрс
Майкл Х. Серрано-Ву
Чунь ЧЖАН
Майкл Пол Каппарелли
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48626502&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201492023(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201492023A1 publication Critical patent/EA201492023A1/ru
Publication of EA027113B1 publication Critical patent/EA027113B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Изобретение относится к соединению формулы (I), способу получения соединений по изобретению и их терапевтическому применению. В изобретении предлагаются также комбинации фармакологически активных агентов и фармацевтические композиции.
EA201492023A 2012-05-04 2013-05-03 Регуляторы пути комплемента и их применение EA027113B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261642798P 2012-05-04 2012-05-04
US201361782820P 2013-03-14 2013-03-14
PCT/IB2013/053546 WO2013164802A1 (en) 2012-05-04 2013-05-03 Complement pathway modulators and uses thereof

Publications (2)

Publication Number Publication Date
EA201492023A1 true EA201492023A1 (ru) 2015-03-31
EA027113B1 EA027113B1 (ru) 2017-06-30

Family

ID=48626502

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492023A EA027113B1 (ru) 2012-05-04 2013-05-03 Регуляторы пути комплемента и их применение

Country Status (25)

Country Link
EP (1) EP2855456B1 (ru)
JP (1) JP6180514B2 (ru)
KR (1) KR20150003903A (ru)
CN (1) CN104603127B (ru)
AP (1) AP2014008040A0 (ru)
AR (1) AR090945A1 (ru)
AU (1) AU2013255470B2 (ru)
BR (1) BR112014027359A2 (ru)
CA (1) CA2872000A1 (ru)
CL (1) CL2014002919A1 (ru)
CR (1) CR20140508A (ru)
EA (1) EA027113B1 (ru)
ES (1) ES2630079T3 (ru)
HK (1) HK1206017A1 (ru)
IL (1) IL235362A0 (ru)
MX (1) MX2014013428A (ru)
PE (1) PE20150623A1 (ru)
PH (1) PH12014502462A1 (ru)
PL (1) PL2855456T3 (ru)
PT (1) PT2855456T (ru)
SG (1) SG11201406973PA (ru)
TN (1) TN2014000449A1 (ru)
TW (1) TW201348199A (ru)
UY (1) UY34781A (ru)
WO (1) WO2013164802A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105229003B (zh) 2013-03-14 2017-03-15 诺华股份有限公司 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN105849090A (zh) * 2013-10-30 2016-08-10 诺华股份有限公司 2-苄基-苯并咪唑补体因子b抑制剂及其用途
CN103755622A (zh) * 2013-12-25 2014-04-30 华东理工大学 合成4,5,6,7-四氘代吲哚-3-乙酸的方法
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
TW202222786A (zh) 2016-02-01 2022-06-16 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
AU2017290593A1 (en) * 2016-06-27 2019-01-03 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
TW202010742A (zh) * 2018-04-06 2020-03-16 美商百歐克斯製藥公司 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
AU2019346464A1 (en) 2018-09-25 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
US20230331710A1 (en) 2020-08-07 2023-10-19 Shanghai Meiyue Biotech Development Co. Ltd Heterocyclic compound, preparation method and use thereof
CN114057758A (zh) 2020-08-07 2022-02-18 上海美悦生物科技发展有限公司 补体因子b抑制剂及其药物组合物、制备方法和用途
WO2023187715A1 (en) * 2022-04-01 2023-10-05 Novartis Ag Complement factor b inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
GB8420919D0 (en) * 1984-08-17 1984-09-19 Beecham Group Plc Compounds
DE19545464A1 (de) * 1995-12-06 1997-06-12 Bayer Ag Benzimidazol-isoindoleninfarbstoffe
ES2295128T3 (es) * 2000-01-17 2008-04-16 Teijin Pharma Limited Derivados de bencimidazol como inhibidores de quimasa humana.
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
MX2007004197A (es) * 2004-10-08 2007-06-15 Schering Corp Antagonistas del receptor de trombina.
WO2007034277A1 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists
CA2655694C (en) * 2006-07-03 2014-12-16 Biovitrum Ab (Publ) 1,4-substituted indoles useful for modulation of the 5-ht6 receptor
JO3265B1 (ar) * 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
MA32975B1 (fr) * 2008-12-22 2012-01-02 Chemocentryx Inc Antagonistes de c5ar
EP2398791A1 (en) * 2009-02-18 2011-12-28 Amgen, Inc INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS
EP2447263A1 (en) * 2010-09-27 2012-05-02 Bioprojet Benzazole derivatives as histamine H4 receptor ligands
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators

Also Published As

Publication number Publication date
JP6180514B2 (ja) 2017-08-16
PL2855456T3 (pl) 2017-09-29
AR090945A1 (es) 2014-12-17
PH12014502462A1 (en) 2014-12-22
TN2014000449A1 (en) 2016-03-30
CA2872000A1 (en) 2013-11-07
TW201348199A (zh) 2013-12-01
EP2855456A1 (en) 2015-04-08
PT2855456T (pt) 2017-07-10
KR20150003903A (ko) 2015-01-09
AU2013255470A1 (en) 2014-11-13
JP2015515976A (ja) 2015-06-04
EP2855456B1 (en) 2017-03-29
WO2013164802A1 (en) 2013-11-07
PE20150623A1 (es) 2015-05-17
AP2014008040A0 (en) 2014-10-31
BR112014027359A2 (pt) 2017-07-18
UY34781A (es) 2013-12-31
CN104603127B (zh) 2016-10-05
HK1206017A1 (en) 2015-12-31
CL2014002919A1 (es) 2015-07-03
MX2014013428A (es) 2015-02-04
CR20140508A (es) 2015-03-13
CN104603127A (zh) 2015-05-06
ES2630079T3 (es) 2017-08-17
AU2013255470B2 (en) 2015-09-17
IL235362A0 (en) 2014-12-31
EA027113B1 (ru) 2017-06-30
SG11201406973PA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201391000A1 (ru) Индольные соединения или их аналоги, полезные для лечения возрастной макулярной дегенерации (amd)
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
IN2014MN02598A (ru)
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201590319A1 (ru) Новые бициклические пиридиноны
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
EA201391524A1 (ru) Производные гликозида и их применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU